- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02994706
A Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF) (HOME-CF)
A Prospective Pilot Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF)
Cystic fibrosis (CF) is the most common fatal inherited condition in Caucasians, causing recurrent chest infections and premature death due to lung failure. When patients develop chest infections their symptoms usually slowly worsen over the course of several days to weeks. Due to this gradual onset, patients often seek medical attention several days or weeks after symptoms start to worsen. The Investigators believe that if they were able to monitor patients more closely they could diagnose and treat chest infections earlier and consequently improve health outcomes.
The HOMECF study aims to investigate whether home monitoring is beneficial for adults with CF. 100 subjects will be randomly allocated, 50 to receive home monitoring and 50 to receive routine clinical care for 12 months. Subjects receiving home monitoring will measure their lung function and symptoms twice weekly and this data will be transmitted to the medical team by means of a modified mobile phone.
the Investigators hypothesize that home monitoring will allow them to diagnose chest infections at an earlier stage and reduce hospital inpatient days. They will also assess the subjects' experience of receiving home monitoring, the impact on body weight and lung function and and conduct a full health economic analysis to assess value for money. They will also ask subjects to collect a urine sample once weekly to allow us to measure urinary levels of inflammatory markers.
Subjects will be recruited at the West Midlands Adult CF Centre in Birmingham. The research team are well placed to carry out the study because it is a large regional adult CF centre with an excellent record of conducting clinical research.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The principal question being answered by this research study is:
1. Does home monitoring reduce the total number of inpatient hospital days in adults with cystic fibrosis (CF) compared to routine clinical care?
The secondary objectives of this research study are to assess:
- The effect of home monitoring on lung function in adults with cystic fibrosis (CF)
- The effect of home monitoring on requirement for antibiotics in adults with CF
- The effect of home monitoring on nutritional status in adults with CF
- The effect of home monitoring on health related quality of life in adults with CF
- Costeffectiveness analysis comparing the home monitoring period with the routine clinical care period
- The patient experience of receiving home monitoring in adults with CF
- Whether urine levels of inflammatory markers correlate with symptoms and lung function in adults with CF
The aim of this study is assess whether home monitoring is beneficial for adults with cystic fibrosis. Overall, 100 subjects will be recruited at the West Midlands Adult Centre and randomly allocated in a 1:1 ratio to receive home monitoring or routine clinical care for 12 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B9 5SS
- Birmingham Heartlands Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- confirmed diagnosis of CF
- age over 18 years
- the requirement for 1 or more admission to hospital to receive intravenous antibiotics over the preceding 24 months
- clinically stable at the time of recruitment
- Patients who give informed consent.
Exclusion Criteria:
- patients who are currently participating in another clinical trial (excluding observational studies)
- pneumothorax or lung surgery within the previous 3 months, eye surgery (e.g. cataract operation) in the previous 4 weeks (since these factors prevent measurement of spirometry)
- Sputum infection with Burkholderia cenocepacia or Mycobacterium abscessus
- Current diagnosis of active allergic bronchopulmonary aspergillosis (ABPA)
- Previous lung transplantation procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Home monitoring
Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer.
This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation.
We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
|
Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
|
Active Comparator: Clinical Care
Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
|
Participants selected for this arm will continue to receive routine clinical care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of inpatient hospital days in the home monitoring group compared to the routine clinical care group
Time Frame: up to 12 months
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FEV1 in the home monitoring group compared to the routine clinical care group
Time Frame: up to 12 months
|
up to 12 months
|
|
Change in FVC in the home monitoring group compared to the routine
Time Frame: up to 12 months
|
up to 12 months
|
|
Days on oral and intravenous antibiotics in the home monitoring group compared to the routine clinical care group
Time Frame: Up to 12 months
|
Up to 12 months
|
|
Change in body weight in the home monitoring group compared to the routine clinical care group
Time Frame: Up to 12 months
|
Up to 12 months
|
|
Change in BMI in the home monitoring group compared to the routine clinical care group
Time Frame: Up to 12 months
|
Up to 12 months
|
|
Change in CFQ-R scores in the home monitoring group compared to the routine clinical care group
Time Frame: Up to 12 months
|
The Cystic Fibrosis Questionnaire Revised version (CFQ-R) is a multiple choice and likert questionnaire split into two sections: Demographics and Quality of Life.
Answers of 'Always' or similar are deemed a higher value than 'Never' or similar.
The total score is gathered by calculating the amount of 'positive' and 'negative' answers - 'positive' answers are those that are lower values (e.g.
never) than those that are higher values (e.g.
'always)
|
Up to 12 months
|
Health economic analysis measured by EQ-5D-5L
Time Frame: Up to 12 months
|
The Euro Quality of Life (EQ5D) is a multiple choice questionnaire split onto sections including Mobility, Self-Care, Usual activities, Pain/Discomfort, and Anxiety/Depression.
For each of these sections, it asks if a person always have issues, some issues or no issues (e.g.
Mobility - I have no problems / I have some problems / I am confined to bed).
The total score is gathered by calculating the amount of 'positive' and 'negative' answers - 'positive' answers are those that are lower values (e.g.
I have no issues) than those that are higher values (e.g.
I am confined to bed).
There is also a scale, ranging from 0 (worst imaginable health) to 100 (best imaginable health) with 99 intervals in between whereby the patient marks where they feel their current health lays.
|
Up to 12 months
|
Health economic analysis measured by ICECAP-A
Time Frame: Up to 12 months
|
The ICEpop CAPability measure for Adults (ICECAP-A) is a multiple choice questionnaire split onto sections including 'Feeling Settled and Secure, Love, Friendship and Support, Being Independent, Achievement and progress, and Enjoyment and pleasure.
For each of these sections, it asks whether a person has no problem, some problems, many problems or total problem with a certain area (e.g.
Being Independent - I can achieve in all aspects of my life / I can achieve in many aspects of my life / I can achieve in some aspects of my life / I am unable to be at all independent).
The total score is gathered by calculating the amount of 'positive' and 'negative' answers - 'positive' answers are those that are lower values (e.g.
I can achieve in all aspects of my life) than those that are higher values (e.g.
I am unable to be at all independent).
|
Up to 12 months
|
Costs associated with caring for each participant and the cost of conducting the study in the home monitoring group compared to the routine clinical care group
Time Frame: Up to 12 months
|
Up to 12 months
|
|
Patient experience assessed by a semi-structured qualitative interview in the home monitoring group compared to the routine clinical care group
Time Frame: Up to 12 months
|
Up to 12 months
|
|
Levels of relevant urine biomarkers in the home monitoring group associated with pulmonary exacerbations
Time Frame: Up to 12 months
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Edward F Nash, MD, Heart of England NHS Foundation Trust
Publications and helpful links
General Publications
- Nash EF, Choyce J, Carrolan V, Justice E, Shaw KL, Sitch A, Mistry H, Whitehouse JL. A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070133. doi: 10.1177/17534666211070133.
- Choyce J, Shaw KL, Sitch AJ, Mistry H, Whitehouse JL, Nash EF. A prospective pilot study of home monitoring in adults with cystic fibrosis (HOME-CF): protocol for a randomised controlled trial. BMC Pulm Med. 2017 Jan 23;17(1):22. doi: 10.1186/s12890-017-0366-x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012135RM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
-
University Hospital, BordeauxCompleted
Clinical Trials on Home Monitoring
-
Silesian Centre for Heart DiseasesNational Center for Research and Development, PolandCompleted
-
Deutsches Herzzentrum MuenchenCompletedImprovement of Treatment SatisfactionGermany
-
Pennington Biomedical Research CenterLouisiana State University Health Care Services DivisionCompletedHypertension | Obesity | Diabetes | OverweightUnited States
-
Biotronik SE & Co. KGTerminatedHeart Block | Bradycardia | Sick Sinus SyndromeUnited Kingdom
-
Biotronik SE & Co. KGCompletedVentricular Fibrillation | Ventricular Tachycardia | Congestive Heart FailureDenmark, Germany, Israel, Australia, Austria, Czech Republic, Latvia
-
Biotronik FranceBiotronik SE & Co. KGCompletedBradycardia | Pacemaker, ArtificialFrance
-
Biotronik SE & Co. KGTerminatedAtrial Fibrillation | Heart Failure (HF)France, Czech Republic, Germany, Netherlands, Belgium, Sweden, United Kingdom
-
Western University, CanadaCompleted
-
Sheba Medical CenterEarlySense Ltd.UnknownMyocardial Infarction | Cardiac SurgeryIsrael
-
Shanghai Jiao Tong University School of MedicineUnknownHypertension | Type 2 Diabetes Mellitus